Product rollout and distribution expansion
搜索文档
Harvard Bioscience targets $22.5M–$24.5M Q4 revenue as backlog reaches two-year high, expanding product rollouts and distribution (NASDAQ:HBIO)
Seeking Alpha· 2025-11-07 07:16
技术访问问题 - 为确保未来正常访问 需在浏览器中启用Javascript和cookies [1] - 启用广告拦截插件可能导致访问被阻止 需禁用插件并刷新页面 [1]
